The short version of GHRH analog fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-01-12 and is reviewed periodically as new material appears.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
| Property | Value | Notes |
|---|---|---|
| Primary target | Growth hormone-releasing hormone receptor | Located on anterior pituitary somatotroph cells. |
| Receptor class | G protein-coupled receptor | Activation increases intracellular cyclic AMP. |
| Main downstream hormone | Growth hormone and insulin-like growth factor 1 | Growth hormone release precedes IGF-1 elevation. |
| Primary studied effect | Reduction in visceral adipose tissue | Measured by computed tomography in clinical trials. |
| Approximate half-life | 26–38 minutes after subcutaneous administration | Values vary by assay and study population. |
Because growth hormone is released in pulses, single measurements can misrepresent overall secretion. Investigators sometimes use repeated sampling or overnight profiles to capture the pattern rather than a single value. Provocative testing, in which a stimulus is given and the response is tracked over time, offers another way to characterize the axis. Each approach carries trade-offs between sensitivity, burden on the participant, and the influence of non-target variables.
Insulin-like growth factor 1 is produced largely in the liver in response to growth hormone signaling. Its concentration shifts over days rather than minutes, which makes it practical for tracking changes across a study period. Interpretation still depends on age, nutritional status, and concurrent illness, all of which independently affect the marker. Reference ranges are therefore stratified, and comparisons are usually made within an individual over time rather than against a single population threshold.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Genetic mutations causing EDMD affect proteins comprising the nuclear membrane.Possibly, in all EDMD subtypes, there is impaired protein importation into the nucleus. Another possibility is that in all subtypes, there is a loss of nuclear structural integrity.
Carbohydrates are the main source of energy in organisms for metabolism. They are an important source of fuel in exercise. A study conducted by the Institute of Food, Nutrition, and Human Health at Massey University investigated the effect of consuming a carbohydrate and electrolyte solution on muscle glycogen use and running capacity on subjects that were on a high carbohydrate diet. The group that consumed the carbohydrate and electrolyte solution before and during exercise experienced greater endurance capacity. This could not be explained by the varying levels of muscle glycogen; however, higher plasma glucose concentration may have led to this result. Dr. Stephen Bailey posits that the central nervous system can sense the influx of carbohydrates and reduces the perceived effort of the exercise, allowing for greater endurance capacity.
== Bibliography == Harrison, Alex. G. (1992). Chemical ionization mass spectrometry (2. ed.). Boca Raton, Fla. [u.a.]: CRC Press. ISBN 9780849342547. Hunt, Donald F.; McEwen, Charles N.; Harvey, T. Michael. (2002). "Positive and negative chemical ionization mass spectrometry using a Townsend discharge ion source". Analytical Chemistry. 47 (11): 1730–1734. doi:10.1021/ac60361a011. Dass, Chhabil (2007). Fundamentals of contemporary mass spectrometry ([Online-Ausg.]. ed.). Hoboken, N.J.: Wiley-Interscience. ISBN 9780470118498.
genetic disorder Any illness, disease, or other health problem directly caused by one or more abnormalities in an organism's genome which are congenital (present at birth) and not acquired later in life. Causes may include a mutation to one or more genes, or a chromosomal abnormality such as an aneuploidy of a particular chromosome. The mutation responsible may occur spontaneously during embryonic development or may be inherited from one or both parents, in which case the genetic disorder is also classified as a hereditary disorder. Though the abnormality itself is present before birth, the actual disease it causes may not develop until much later in life; some genetic disorders do not necessarily guarantee eventual disease but simply increase the risk of developing it.
Sources: en.wikipedia.org
Le Havre's festival calendar is punctuated by a wide range of events. In spring a Children's Book Festival was recently created. In May there is the Fest Yves, a Breton festival in the Saint-François district. On the beach of Le Havre and Sainte-Adresse there is a jazz festival called Dixie Days in June. In July, detective novels are featured in the Polar room at the Beach hosted by The Black Anchors. Between the latter also in the context of Z'Estivales is an event offering many shows of street art throughout the summer supplemented by the festival of world music MoZaïques at the fort of Sainte-Adresse in August since 2010. In mid-August there is a Flower parade which passes through the streets of the central city. In the first weekend of September the marine element is highlighted in the Festival of the Sea. This is a race between Le Havre and Bahia in Brazil. Also every November there is a fair held in the Docks Café. The Autumn Festival in Normandy, organized by the departments of Seine-Maritime and Eure, and the Region of Normandy, runs from September to November and offers numerous concerts throughout the region as well as theatre performances and dance. In late October, since 2009, there is rock music festival which has been at the fort of Tourneville since the moving of the Papa's Production association site there. The West Park Festival, after its inauguration in 2004, has been held in the park of the town hall of Harfleur. Since 1 June 2006 a Biennale of contemporary Art has been organized by the group Partouche.
Gus Sackey (David Jonsson) is a new grad at Pierpoint, and one of the series' protagonists during the first two series. He is initially assigned to the Investment Banking Division (IBD) and transferred to the CPS desk after the death of his colleague Hari Dhar. Gus is openly gay and hails from an elite background, having graduated literae humaniores from both Eton College and the University of Oxford. Despite his upper-class upbringing, Gus is shown to be humble and morally principled, and feels undervalued within Pierpoint's cutthroat work culture. In series 1, Gus struggles to find a clear role after his team is dissolved and repeatedly alienates senior staff through his bluntness and frustration, including London office head Sara Dhadwal and his manager Clement Cowan. He also rekindles an affair with his former classmate Theo Tuck. On RIF day, Gus delivers a deliberately unserious presentation—beginning by reading from a note written as part of a bet—before walking out, and is not offered a permanent position. In series 2, Gus re-emerges working in politics after striking up a connection with MP Aurore Adekunle, who hires him as an aide. Gus feels fulfilled by the work—which largely involves speaking with everyday constituents about their struggles—despite his sister Sadie's objections. While working for Aurore, Gus begins a relationship with Leo Bloom, the son of hedge fund manager Jesse Bloom, and later leaks confidential government information about the approval of Amazon’s acquisition of pharmaceutical company FastAide to Harper.
In 1877 at Hooghly (near Kolkata), Herschel instituted the use of fingerprints on contracts and deeds, and he registered government pensioners' fingerprints to prevent the collection of money by relatives after a pensioner's death. In 1880, Henry Faulds, a Scottish surgeon in a Tokyo hospital, published his first paper on the subject in the scientific journal Nature, discussing the usefulness of fingerprints for identification and proposing a method to record them with printing ink. He established their first classification and was also the first to identify fingerprints left on a vial. Returning to the UK in 1886, he offered the concept to the Metropolitan Police in London, but it was dismissed at that time. Faulds wrote to Charles Darwin with a description of his method, but, too old and ill to work on it, Darwin gave the information to his cousin, Francis Galton, who was interested in anthropology. Having been thus inspired to study fingerprints for ten years, Galton published a detailed statistical model of fingerprint analysis and identification and encouraged its use in forensic science in his book Finger Prints. He had calculated that the chance of a "false positive" (two different individuals having the same fingerprints) was about 1 in 64 billion.
Sources: en.wikipedia.org
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Binding stimulates cyclic AMP signaling and growth hormone secretion. This is the same receptor used by endogenous GHRH.
It does not act directly on adipose tissue as a primary mechanism. Instead, it increases endogenous growth hormone, which then influences lipolysis and fat distribution. The reduction in visceral fat is an indirect pharmacodynamic effect.
Tesamorelin acts upstream at the pituitary to amplify natural pulsatile growth hormone release. Growth hormone injections provide exogenous hormone and bypass pituitary regulation. The two approaches therefore differ in feedback control and hormonal dynamics.
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.